Journal of the COPD Foundation Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient-Powered Research N
![Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial - The Lancet Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/2119203774/2090550647/gr1.gif)
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial - The Lancet
![Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis | Journal of Investigative Medicine Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis | Journal of Investigative Medicine](https://jim.bmj.com/content/jim/69/8/1391/F4.large.jpg)
Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis | Journal of Investigative Medicine
![Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long- acting β2-agonists/long-acting muscarinic antagonists Kishore N, Moitra S, Sircar M - Indian J Respir Care Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long- acting β2-agonists/long-acting muscarinic antagonists Kishore N, Moitra S, Sircar M - Indian J Respir Care](https://www.ijrc.in/articles/2020/9/2/images/IndianJRespirCare_2020_9_2_162_289093_t4.jpg)
Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long- acting β2-agonists/long-acting muscarinic antagonists Kishore N, Moitra S, Sircar M - Indian J Respir Care
![PDF] Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma | Semantic Scholar PDF] Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ba821e4f4e613ea4b521b14fa18ccc545a19bf50/4-Table1-1.png)
PDF] Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma | Semantic Scholar
![The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review | European Respiratory Society The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review | European Respiratory Society](https://err.ersjournals.com/content/errev/31/164/210196/F1.large.jpg)
The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review | European Respiratory Society
![Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs | Journal of Pharmacology and Experimental Therapeutics Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/330/2/660/F1.large.jpg)
Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs | Journal of Pharmacology and Experimental Therapeutics
![Long‑acting muscarinic antagonist and long‑acting β2‑agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery Long‑acting muscarinic antagonist and long‑acting β2‑agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery](https://www.spandidos-publications.com/article_images/mco/8/5/mco-08-05-0647-g01.jpg)
Long‑acting muscarinic antagonist and long‑acting β2‑agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
![Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long- acting β2-agonists/long-acting muscarinic antagonists Kishore N, Moitra S, Sircar M - Indian J Respir Care Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long- acting β2-agonists/long-acting muscarinic antagonists Kishore N, Moitra S, Sircar M - Indian J Respir Care](https://www.ijrc.in/articles/2020/9/2/images/IndianJRespirCare_2020_9_2_162_289093_f3.jpg)